Core Viewpoint - The strategic partnership between 帝王国际投资 (Emperor International Investment) and 荣裕合集团香港有限公司 (Rongyuhe Group) aims to explore collaboration opportunities in the health industry, e-commerce, and liquor sectors, leveraging each other's resources for sustainable growth and competitive advantage [1] Group 1: Strategic Partnership - The agreement was signed on November 3, 2025, establishing a long-term strategic partnership [1] - The collaboration focuses on the health industry, e-commerce, and liquor business sectors [1] Group 2: Partner Profile - 荣裕合集团 is a Hong Kong-registered company active in the global digital economy, promoting the integration of digital technology with traditional industries [1] - The group has a diverse business focus, including digital economy ecosystem construction, "intangible cultural heritage + e-commerce" innovation, and digitalization of traditional Chinese medicine [1] Group 3: Business Philosophy and Strategy - 荣裕合集团 emphasizes a "pain-free consumption" concept in e-commerce, aiming to enhance consumer shopping experiences by optimizing processes and reducing intermediaries [1] - The company has initiated digital cooperation projects in several countries along the "Belt and Road" initiative, showcasing its global strategic layout and resource integration capabilities [1] Group 4: Goals of the Collaboration - The partnership aims to integrate the strengths of both companies, adhering to principles of openness, mutual trust, and win-win cooperation [1] - The collaboration seeks to create new business models that drive future development and enhance overall competitiveness and sustainability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 King International Investment Limited （股份代號：928） 帝 王 國 際 投 資 有 限 公 司 自願性公佈 戰略合作協議 本公佈乃由帝王國際投資有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願刊發， 旨在向本公司的股東及潛在投資者公開本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年十一月三日，本公司與榮裕 合集團香港有限公司（「合作方」）訂立戰略合作協議（「協議」），雙方同意建立長期戰略合 作夥伴關係，共同探索在大健康產業、商城及白酒等業務領域的合作機會。 榮裕合集團為一家在香港註冊成立，活躍於全球數字經濟領域的企業，積極推動數字經 濟與傳統產業的融合創新。合作方致力於通過數字技術賦能產業發展，業務觸角已延申 至跨境電商、智慧物流、中醫藥數字化等多個前沿領域，具備豐富的行業資源與專業實力。 榮裕合集團的業務多元且具有前 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00928 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000,000 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有 ...

Core Insights - The biotechnology sector in the Hong Kong stock market has shown strong performance, with several stocks experiencing significant gains today, particularly药捷安康-B which surged over 30% [1] Stock Performance Summary - 药捷安康-B: Increased by 31.25%, latest price at 218.000, total market value of 86.524 billion, year-to-date increase of 1557.79% [2] - 康宁杰瑞制药-B: Increased by 7.15%, latest price at 14.680, total market value of 14.245 billion, year-to-date increase of 319.43% [2] - 帝王国际投资: Increased by 5.50%, latest price at 0.115, total market value of 0.0213 billion, year-to-date increase of 155.56% [2] - 映恩生物-B: Increased by 5.00%, latest price at 336.000, total market value of 29.58 billion, year-to-date increase of 255.18% [2] - 基石药业-B: Increased by 4.66%, latest price at 7.190, total market value of 10.612 billion, year-to-date increase of 212.61% [2] - 三叶草生物-B: Increased by 4.39%, latest price at 2.140, total market value of 2.776 billion, year-to-date increase of 787.97% [2] - 百奥塞图-B: Increased by 3.86%, latest price at 24.220, total market value of 9.673 billion, year-to-date increase of 184.94% [2] - 来凯医药-B: Increased by 3.71%, latest price at 14.540, total market value of 6.49217 billion, year-to-date increase of 55.18% [2] - 君实生物: Increased by 3.29%, latest price at 27.600, total market value of 28.337 billion, year-to-date increase of 138.34% [2] - MIRXES-B: Increased by 3.26%, latest price at 72.900, total market value of 20.145 billion, year-to-date increase of 212.88% [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 帝王國際投資有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00928 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.05 | HKD | | 500,000,000 | 本 ...

Core Viewpoint - Emperor International Investment (00928.HK) announced that its shares will resume trading today, September 22, 2025 [1] Summary by Category - Company Announcement - The company has officially stated that its shares will be available for trading starting at 9:00 AM on September 22, 2025 [1]

Core Insights - The company reported a significant decline in revenue, with earnings of HKD 40.765 million for the year ending March 31, 2025, representing a year-on-year decrease of 82.6% [1] - The company experienced a loss attributable to owners of HKD 47.453 million, compared to a profit of HKD 15.818 million in the same period last year [1] - Basic loss per share was HKD 0.0256 [1] Financial Performance - The group achieved a gross profit of approximately HKD 12.73 million for the year ending March 31, 2025, down from approximately HKD 37.79 million for the year ending March 31, 2024 [1] - The overall gross profit margin increased to 31.23% from 16.17% in the previous year [1] - The gross profit was primarily attributed to lower-margin liquor sales, with approximately 100% of sales coming from liquor sales compared to 51.29% in the previous year [1] Stock Market Activity - The company has applied to resume trading of its shares on the Hong Kong Stock Exchange starting from September 22, 2025, at 9:00 AM [1]

智通财经APP讯，帝王国际投资(00928)发布截至2025年3月31日止年度业绩，收益4076.5万港元，同比 下降82.6%;公司拥有人应占亏损4745.3万港元，上年同期溢利1581.8万港元;每股基本亏损2.56港仙。 截至2025年3月31日止年度，集团取得毛利约1273万港元(截至2024年3月31日止年度：约3779万港元)。 集团的整体毛利率为31.23%(截至2024年3月31日止年度：16.17%)。截至2025年及2024年3月31日止年 度，集团的整体毛利主要归因于毛利率较低的酒类销售。本年度约100.00%的销售额来自酒类销售(截至 2024年3月31日止年度：51.29%)。 公司已申请于2025年9月22日上午九时正起恢复公司股份于联交所买卖。 ...

Group 1 - The company, Emperor International Investment (00928.HK), announced a delay in the publication and/or distribution of its 2025 annual results and annual report due to the need for additional time to complete necessary audit procedures [1] - The delay is attributed to the auditor not having received certain confirmations required for the audit, such as bank confirmation letters [1] - Trading of the company's shares remains suspended as a result of these delays [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 King International Investment Limited （股份代號：928） 帝 王 國 際 投 資 有 限 公 司 Life Healthcare Group Limited (1)進一步延遲刊發二零二五年全年業績； (2)董事會會議進一步延期 及 (3)繼續暫停買賣 茲提述本公司日期為二零二五年六月三十日、二零二五年七月十八日、二零二五年八月 八日及二零二五年八月二十二日之公佈（「該公佈」），內容有關（其中包括）(i)延遲刊發本 集團截至二零二五年三月三十一日止財政年度之全年業績（「二零二五年全年業績」）；(ii) 董事會會議延期；及(iii)暫停買賣。除另有界定外，本公佈所用詞彙與該公佈所界定者具 有相同涵義。 根據目前情況及最近與核數師的討論，鑑於本集團審核進度的最新情況，需要額外時間 以完成必要的審核程序，包括但不限於(i)核數師於本公佈日期仍未收到審核所需的若干 確認（如 ...